ID   BMR1B_HUMAN             Reviewed;         502 AA.
AC   O00238; B2R953; B4DSV1; P78366;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   12-OCT-2022, entry version 220.
DE   RecName: Full=Bone morphogenetic protein receptor type-1B;
DE            Short=BMP type-1B receptor;
DE            Short=BMPR-1B;
DE            EC=2.7.11.30 {ECO:0000250|UniProtKB:P36898};
DE   AltName: CD_antigen=CDw293;
DE   Flags: Precursor;
GN   Name=BMPR1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=9178898; DOI=10.1038/sj.onc.1200964;
RA   Ide H., Katoh M., Sasaki H., Yoshida T., Aoki K., Nawa Y., Osada Y.,
RA   Sugimura T., Terada M.;
RT   "Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and
RT   its expression in prostate cancer in comparison with other BMPRs.";
RL   Oncogene 14:1377-1382(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=10051328; DOI=10.1007/s003359900990;
RA   Astroem A.-K., Jin D.F., Imamura T., Roijer E., Rosenzweig B., Miyazono K.,
RA   ten Dijke P., Stenman G.;
RT   "Chromosomal localization of three human genes encoding bone morphogenetic
RT   protein receptors.";
RL   Mamm. Genome 10:299-302(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH GDF5.
RX   PubMed=24098149; DOI=10.1371/journal.pgen.1003846;
RA   Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J.,
RA   Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S.,
RA   Doelken S.C., Seemann P.;
RT   "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.";
RL   PLoS Genet. 9:E1003846-E1003846(2013).
RN   [8]
RP   INTERACTION WITH SCUBE3.
RX   PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015;
RG   Genomics England Research Consortium;
RA   Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R.,
RA   Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S.,
RA   Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E.,
RA   Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R.,
RA   Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M.,
RA   Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H.,
RA   Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C.,
RA   Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C.,
RA   Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.;
RT   "SCUBE3 loss-of-function causes a recognizable recessive developmental
RT   disorder due to defective bone morphogenetic protein signaling.";
RL   Am. J. Hum. Genet. 108:115-133(2021).
RN   [9]
RP   VARIANTS BDA2 LYS-200 AND TRP-486, AND CHARACTERIZATION OF VARIANTS BDA2
RP   LYS-200 AND TRP-486.
RX   PubMed=14523231; DOI=10.1073/pnas.2133476100;
RA   Lehmann K., Seemann P., Stricker S., Sammar M., Meyer B., Suering K.,
RA   Majewski F., Tinschert S., Grzeschik K.-H., Mueller D., Knaus P.,
RA   Nuernberg P., Mundlos S.;
RT   "Mutations in bone morphogenetic protein receptor 1B cause brachydactyly
RT   type A2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12277-12282(2003).
RN   [10]
RP   INVOLVEMENT IN AMD3.
RX   PubMed=15805157; DOI=10.1136/jmg.2004.023564;
RA   Demirhan O., Tuerkmen S., Schwabe G.C., Soyupak S., Akguel E., Tastemir D.,
RA   Karahan D., Mundlos S., Lehmann K.;
RT   "A homozygous BMPR1B mutation causes a new subtype of acromesomelic
RT   chondrodysplasia with genital anomalies.";
RL   J. Med. Genet. 42:314-317(2005).
RN   [11]
RP   VARIANT BRACHYDACTYLY TYPE C/BDA2 GLN-486.
RX   PubMed=16957682; DOI=10.1038/sj.ejhg.5201708;
RA   Lehmann K., Seemann P., Boergermann J., Morin G., Reif S., Knaus P.,
RA   Mundlos S.;
RT   "A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type
RT   C/symphalangism-like phenotype or brachydactyly type A2.";
RL   Eur. J. Hum. Genet. 14:1248-1254(2006).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-31; TRP-149; HIS-224; ASN-297 AND
RP   GLN-371.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [13]
RP   VARIANT AMD3 ARG-53, AND CHARACTERIZATION OF VARIANT AMD3 ARG-53.
RX   PubMed=24129431; DOI=10.1038/ejhg.2013.222;
RA   Graul-Neumann L.M., Deichsel A., Wille U., Kakar N., Koll R., Bassir C.,
RA   Ahmad J., Cormier-Daire V., Mundlos S., Kubisch C., Borck G., Klopocki E.,
RA   Mueller T.D., Doelken S.C., Seemann P.;
RT   "Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic
RT   chondrodysplasia-type Grebe.";
RL   Eur. J. Hum. Genet. 22:726-733(2014).
RN   [14]
RP   INVOLVEMENT IN BDA1D, VARIANT BDA1D ASN-325, AND CHARACTERIZATION OF
RP   VARIANT BDA1D ASN-325.
RX   PubMed=25758993; DOI=10.1038/ejhg.2015.38;
RA   Racacho L., Byrnes A.M., MacDonald H., Dranse H.J., Nikkel S.M.,
RA   Allanson J., Rosser E., Underhill T.M., Bulman D.E.;
RT   "Two novel disease-causing variants in BMPR1B are associated with
RT   brachydactyly type A1.";
RL   Eur. J. Hum. Genet. 23:1640-1645(2015).
RN   [15]
RP   VARIANT AMD3 CYS-31, AND CHARACTERIZATION OF VARIANT AMD3 CYS-31.
RX   PubMed=26105076; DOI=10.1186/s13023-015-0299-5;
RA   Stange K., Desir J., Kakar N., Mueller T.D., Budde B.S., Gordon C.T.,
RA   Horn D., Seemann P., Borck G.;
RT   "A hypomorphic BMPR1B mutation causes du Pan acromesomelic dysplasia.";
RL   Orphanet J. Rare Dis. 10:84-84(2015).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two
CC       type II and two type I transmembrane serine/threonine kinases. Type II
CC       receptors phosphorylate and activate type I receptors which
CC       autophosphorylate, then bind and activate SMAD transcriptional
CC       regulators. Receptor for BMP7/OP-1 and GDF5. Positively regulates
CC       chondrocyte differentiation through GDF5 interaction.
CC       {ECO:0000250|UniProtKB:P36898}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC         Evidence={ECO:0000250|UniProtKB:P36898};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44881;
CC         Evidence={ECO:0000250|UniProtKB:P36898};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30; Evidence={ECO:0000250|UniProtKB:P36898};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18674;
CC         Evidence={ECO:0000250|UniProtKB:P36898};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with high affinity with GDF5; positively regulates
CC       chondrocyte differentiation. Interacts with SCUBE3 (PubMed:33308444).
CC       {ECO:0000269|PubMed:24098149, ECO:0000269|PubMed:33308444}.
CC   -!- INTERACTION:
CC       O00238; P12643: BMP2; NbExp=3; IntAct=EBI-7527193, EBI-1029262;
CC       O00238; P43026: GDF5; NbExp=7; IntAct=EBI-7527193, EBI-8571476;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P36898};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O00238-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00238-2; Sequence=VSP_045100;
CC   -!- PTM: Autophosphorylated. {ECO:0000250|UniProtKB:P36898}.
CC   -!- DISEASE: Acromesomelic dysplasia 3 (AMD3) [MIM:609441]: A form of
CC       acromesomelic dysplasia, a skeletal disorder characterized by short
CC       stature, very short limbs and hand/foot malformations. The severity of
CC       limb abnormalities increases from proximal to distal with profoundly
CC       affected hands and feet showing brachydactyly and/or rudimentary
CC       fingers (knob-like fingers). AMD3 is an autosomal recessive form
CC       characterized by bilateral aplasia of the fibula, severe brachydactyly,
CC       and fusion of carpal and tarsal bones. {ECO:0000269|PubMed:15805157,
CC       ECO:0000269|PubMed:24129431, ECO:0000269|PubMed:26105076}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Brachydactyly A2 (BDA2) [MIM:112600]: A form of brachydactyly.
CC       Brachydactyly defines a group of inherited malformations characterized
CC       by shortening of the digits due to abnormal development of the
CC       phalanges and/or the metacarpals. In brachydactyly type A2 shortening
CC       of the middle phalanges is confined to the index finger and the second
CC       toe, all other digits being more or less normal. Because of a rhomboid
CC       or triangular shape of the affected middle phalanx, the end of the
CC       second finger usually deviates radially. {ECO:0000269|PubMed:14523231,
CC       ECO:0000269|PubMed:16957682}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Brachydactyly A1, D (BDA1D) [MIM:616849]: A form of
CC       brachydactyly type A1. Brachydactyly defines a group of inherited
CC       malformations characterized by shortening of the digits due to abnormal
CC       development of the phalanges and/or the metacarpals. Brachydactyly type
CC       A1 is characterized by middle phalanges of all the digits rudimentary
CC       or fused with the terminal phalanges. The proximal phalanges of the
CC       thumbs and big toes are short. BDA1D inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:25758993}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D89675; BAA19765.1; -; mRNA.
DR   EMBL; U89326; AAC28131.1; -; mRNA.
DR   EMBL; AK299930; BAG61763.1; -; mRNA.
DR   EMBL; AK313642; BAG36400.1; -; mRNA.
DR   EMBL; AC004061; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093634; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105395; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX06060.1; -; Genomic_DNA.
DR   EMBL; BC047773; AAH47773.1; -; mRNA.
DR   EMBL; BC069796; AAH69796.1; -; mRNA.
DR   EMBL; BC069803; AAH69803.1; -; mRNA.
DR   CCDS; CCDS3642.1; -. [O00238-1]
DR   CCDS; CCDS58919.1; -. [O00238-2]
DR   RefSeq; NP_001194.1; NM_001203.2. [O00238-1]
DR   RefSeq; NP_001243721.1; NM_001256792.1. [O00238-1]
DR   RefSeq; NP_001243722.1; NM_001256793.1. [O00238-2]
DR   RefSeq; NP_001243723.1; NM_001256794.1. [O00238-1]
DR   RefSeq; XP_011530503.1; XM_011532201.2. [O00238-1]
DR   RefSeq; XP_016864047.1; XM_017008558.1. [O00238-1]
DR   RefSeq; XP_016864048.1; XM_017008559.1. [O00238-1]
DR   RefSeq; XP_016864049.1; XM_017008560.1. [O00238-1]
DR   RefSeq; XP_016864050.1; XM_017008561.1. [O00238-1]
DR   PDB; 3MDY; X-ray; 2.05 A; A/C=168-502.
DR   PDBsum; 3MDY; -.
DR   AlphaFoldDB; O00238; -.
DR   SMR; O00238; -.
DR   BioGRID; 107126; 79.
DR   IntAct; O00238; 7.
DR   MINT; O00238; -.
DR   STRING; 9606.ENSP00000401907; -.
DR   BindingDB; O00238; -.
DR   ChEMBL; CHEMBL5476; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O00238; -.
DR   GuidetoPHARMACOLOGY; 1789; -.
DR   iPTMnet; O00238; -.
DR   PhosphoSitePlus; O00238; -.
DR   BioMuta; BMPR1B; -.
DR   jPOST; O00238; -.
DR   MassIVE; O00238; -.
DR   MaxQB; O00238; -.
DR   PaxDb; O00238; -.
DR   PeptideAtlas; O00238; -.
DR   PRIDE; O00238; -.
DR   ProteomicsDB; 47802; -. [O00238-1]
DR   Antibodypedia; 4045; 677 antibodies from 35 providers.
DR   DNASU; 658; -.
DR   Ensembl; ENST00000264568.8; ENSP00000264568.4; ENSG00000138696.11. [O00238-1]
DR   Ensembl; ENST00000394931.1; ENSP00000378389.1; ENSG00000138696.11. [O00238-1]
DR   Ensembl; ENST00000440890.7; ENSP00000401907.2; ENSG00000138696.11. [O00238-2]
DR   Ensembl; ENST00000509540.6; ENSP00000421671.1; ENSG00000138696.11. [O00238-1]
DR   Ensembl; ENST00000512312.5; ENSP00000425444.1; ENSG00000138696.11. [O00238-1]
DR   Ensembl; ENST00000515059.6; ENSP00000426617.1; ENSG00000138696.11. [O00238-1]
DR   Ensembl; ENST00000672698.1; ENSP00000500035.1; ENSG00000138696.11. [O00238-1]
DR   GeneID; 658; -.
DR   KEGG; hsa:658; -.
DR   MANE-Select; ENST00000515059.6; ENSP00000426617.1; NM_001203.3; NP_001194.1.
DR   UCSC; uc003htm.5; human. [O00238-1]
DR   CTD; 658; -.
DR   DisGeNET; 658; -.
DR   GeneCards; BMPR1B; -.
DR   GeneReviews; BMPR1B; -.
DR   HGNC; HGNC:1077; BMPR1B.
DR   HPA; ENSG00000138696; Tissue enhanced (brain, cervix, prostate).
DR   MalaCards; BMPR1B; -.
DR   MIM; 112600; phenotype.
DR   MIM; 603248; gene.
DR   MIM; 609441; phenotype.
DR   MIM; 616849; phenotype.
DR   neXtProt; NX_O00238; -.
DR   OpenTargets; ENSG00000138696; -.
DR   Orphanet; 2098; Acromesomelic dysplasia, Grebe type.
DR   Orphanet; 93388; Brachydactyly type A1.
DR   Orphanet; 93396; Brachydactyly type A2.
DR   Orphanet; 93384; Brachydactyly type C.
DR   Orphanet; 2639; Fibular aplasia-complex brachydactyly syndrome.
DR   PharmGKB; PA25387; -.
DR   VEuPathDB; HostDB:ENSG00000138696; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   GeneTree; ENSGT00940000155919; -.
DR   HOGENOM; CLU_000288_8_1_1; -.
DR   InParanoid; O00238; -.
DR   OMA; SWNNERE; -.
DR   OrthoDB; 776697at2759; -.
DR   PhylomeDB; O00238; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; O00238; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; O00238; -.
DR   SIGNOR; O00238; -.
DR   BioGRID-ORCS; 658; 15 hits in 1101 CRISPR screens.
DR   ChiTaRS; BMPR1B; human.
DR   EvolutionaryTrace; O00238; -.
DR   GeneWiki; BMPR1B; -.
DR   GenomeRNAi; 658; -.
DR   Pharos; O00238; Tchem.
DR   PRO; PR:O00238; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; O00238; protein.
DR   Bgee; ENSG00000138696; Expressed in calcaneal tendon and 158 other tissues.
DR   ExpressionAtlas; O00238; baseline and differential.
DR   Genevisible; O00238; HS.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL.
DR   GO; GO:0036122; F:BMP binding; IEA:Ensembl.
DR   GO; GO:0098821; F:BMP receptor activity; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019211; F:phosphatase activator activity; IEA:Ensembl.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IBA:GO_Central.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl.
DR   GO; GO:0002063; P:chondrocyte development; ISS:AgBase.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central.
DR   GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase.
DR   GO; GO:0001654; P:eye development; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:1902731; P:negative regulation of chondrocyte proliferation; ISS:AgBase.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0001550; P:ovarian cumulus expansion; ISS:UniProtKB.
DR   GO; GO:0042698; P:ovulation cycle; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl.
DR   Gene3D; 2.10.60.10; -; 1.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chondrogenesis; Disease variant; Disulfide bond; Dwarfism; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Receptor; Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..13
FT                   /evidence="ECO:0000255"
FT   CHAIN           14..502
FT                   /note="Bone morphogenetic protein receptor type-1B"
FT                   /id="PRO_0000024412"
FT   TOPO_DOM        14..126
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        127..148
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        149..502
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          174..203
FT                   /note="GS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00585"
FT   DOMAIN          204..494
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        332
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         210..218
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         231
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DISULFID        32..53
FT                   /evidence="ECO:0000250|UniProtKB:P36898"
FT   DISULFID        34..38
FT                   /evidence="ECO:0000250|UniProtKB:P36898"
FT   DISULFID        47..71
FT                   /evidence="ECO:0000250|UniProtKB:P36898"
FT   DISULFID        81..95
FT                   /evidence="ECO:0000250|UniProtKB:P36898"
FT   DISULFID        96..102
FT                   /evidence="ECO:0000250|UniProtKB:P36898"
FT   VAR_SEQ         1
FT                   /note="M -> MGWLEELNWQLHIFLLILLSMHTRANFLDNM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045100"
FT   VARIANT         31
FT                   /note="R -> C (in AMD3; unknown pathological significance;
FT                   mouse BMPR1B construct containing this mutation shows
FT                   reduced GDF5-dependent receptor activation, mouse BMPR1B
FT                   construct containing this mutation shows no loss of cell
FT                   membrane localization; dbSNP:rs745854387)"
FT                   /evidence="ECO:0000269|PubMed:26105076"
FT                   /id="VAR_075520"
FT   VARIANT         31
FT                   /note="R -> H (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs200035802)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041401"
FT   VARIANT         53
FT                   /note="C -> R (in AMD3; mouse BMPR1B construct containing
FT                   this mutation shows loss of GDF5-dependent receptor
FT                   activation, chicken BMPR1B construct containing this
FT                   mutation does not show reduced chondrocyte differentiation,
FT                   mouse BMPR1B construct containing this mutation shows no
FT                   loss of cell membrane localization; dbSNP:rs863225041)"
FT                   /evidence="ECO:0000269|PubMed:24129431"
FT                   /id="VAR_075521"
FT   VARIANT         149
FT                   /note="R -> W (in dbSNP:rs34231464)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041402"
FT   VARIANT         200
FT                   /note="I -> K (in BDA2; in animal models loss of kinase
FT                   activity and loss of positive regulation of chondrocyte
FT                   differentiation; dbSNP:rs121434417)"
FT                   /evidence="ECO:0000269|PubMed:14523231"
FT                   /id="VAR_023819"
FT   VARIANT         224
FT                   /note="R -> H (in dbSNP:rs35973133)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041403"
FT   VARIANT         297
FT                   /note="D -> N (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041404"
FT   VARIANT         325
FT                   /note="K -> N (in BDA1D; acts in a dominant-negative
FT                   manner; dbSNP:rs869025614)"
FT                   /evidence="ECO:0000269|PubMed:25758993"
FT                   /id="VAR_076406"
FT   VARIANT         371
FT                   /note="R -> Q (in dbSNP:rs34970181)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041405"
FT   VARIANT         486
FT                   /note="R -> Q (in brachydactyly type C and BDA2; with also
FT                   additional features of symphalangism-1; dbSNP:rs121434419)"
FT                   /evidence="ECO:0000269|PubMed:16957682"
FT                   /id="VAR_037967"
FT   VARIANT         486
FT                   /note="R -> W (in BDA2; in animal models no effect on
FT                   kinase activity but strongly decreased positive regulation
FT                   of chondrocyte differentiation; dbSNP:rs121434418)"
FT                   /evidence="ECO:0000269|PubMed:14523231"
FT                   /id="VAR_023820"
FT   HELIX           176..186
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          190..192
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           194..197
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           200..203
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          205..213
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          216..223
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          226..234
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           235..237
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           238..248
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          261..268
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           270..272
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          274..279
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           287..293
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           298..316
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          337..340
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   STRAND          346..348
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           375..377
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           380..383
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           393..411
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   TURN            426..430
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           437..444
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           455..459
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           461..473
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           478..480
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   HELIX           484..496
FT                   /evidence="ECO:0007829|PDB:3MDY"
FT   TURN            497..499
FT                   /evidence="ECO:0007829|PDB:3MDY"
SQ   SEQUENCE   502 AA;  56930 MW;  B283D9BF45535C79 CRC64;
     MLLRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED
     DSGLPVVTSG CLGLEGSDFQ CRDTPIPHQR RSIECCTERN ECNKDLHPTL PPLKNRDFVD
     GPIHHRALLI SVTVCSLLLV LIILFCYFRY KRQETRPRYS IGLEQDETYI PPGESLRDLI
     EQSQSSGSGS GLPLLVQRTI AKQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS
     WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS
     MLKLAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD
     TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV
     EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS
     RLTALRVKKT LAKMSESQDI KL
//
